Retrotrope is striving to change aging as we know it, so that people do not have to suffer the ravages of many degenerative diseases. Retrotope is a clinical stage pharmaceutical startup that is leading the advance of a revolutionary new unified theory of aging and degeneration that can result in dramatically new approaches to therapy. It is creating a new category of drugs composed of proprietary compounds that target degenerative diseases, such as Parkinson's, Alzheimer's, mitochondrial myopathies and retinopathies.
Retrotope is currently assessing technical proof of principle, regulatory requirements, and viability of several products in multiple market segments.
Retrotope announced today the successful completion of the first dose cohort and the opening of patient enrollment for the highest dose cohort in its ongoing 28-day study of orally dosed RT001 in Friedreich’s ataxia (FA) patients. RT001 was well tolerated and no serious adverse events or dose limiting toxicities were observed.
Presentation by Dr. Harry Saal about how RT001 addresses the orphan disease Friedreich's ataxia.
(October 12, 2015)